학술논문
Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C
Document Type
Report
Author
Source
Bosnian Journal of Basic Medical Sciences. May 2013, Vol. 13 Issue 2, p84, 5 p.
Subject
Language
English
ISSN
1512-8601
Abstract
INTRODUCTION Chronic liver disease is commonly associated with complex hemostatic defects that include impaired synthesis of a number of coagulation proteins and their synthesis is variably impaired in liver disease [...]
Previous studies have reported reduced synthesis of various hemostatic factors in patients with chronic liver disease. Whether changes in plasma levels of these proteins reflect recovered liver synthetic function following virological eradication therapy has not been approved yet. The aim of the study was to determine the impact of sustained viral suppression achieved with pegylated interferon alpha and ribavirin on hemostatic parameters including natural anticoagulants in patients with chronic hepatitis C. The following coagulation screening tests were obtained in thirty patients with chronic viral hepatitis C before and after completion of antiviral treatment: activated partial thromboplastin time, prothrombin time, plasma fibrinogen and natural anticoagulant proteins antithrombin III, protein C (PC) and total protein S (PS) activity. Only patients who achieved durable virus suppression were included. The mean PC and PS levels were significantly lower in patients with chronic viral hepatitis C before antiviral therapy than in healthy controls (79.04 [+ or -] 16.19 % vs. 109.92 [+ or -] 21.33% and 54.04 [+ or -] 16.11% vs. 87.60 [+ or -] 8.15%, respectively; (p Protein C and protein S are sensitive markers of hepatocyte synthetic impairment and are valuable markers in monitoring the efficacy of antiviral treatment in chronic hepatitis C patients. Larger studies are needed to confirm our results. KEY WORDS: chronic hepatitis C, liver disease, interferon alpha, anticoagulation proteins, Protein C, Protein S
Previous studies have reported reduced synthesis of various hemostatic factors in patients with chronic liver disease. Whether changes in plasma levels of these proteins reflect recovered liver synthetic function following virological eradication therapy has not been approved yet. The aim of the study was to determine the impact of sustained viral suppression achieved with pegylated interferon alpha and ribavirin on hemostatic parameters including natural anticoagulants in patients with chronic hepatitis C. The following coagulation screening tests were obtained in thirty patients with chronic viral hepatitis C before and after completion of antiviral treatment: activated partial thromboplastin time, prothrombin time, plasma fibrinogen and natural anticoagulant proteins antithrombin III, protein C (PC) and total protein S (PS) activity. Only patients who achieved durable virus suppression were included. The mean PC and PS levels were significantly lower in patients with chronic viral hepatitis C before antiviral therapy than in healthy controls (79.04 [+ or -] 16.19 % vs. 109.92 [+ or -] 21.33% and 54.04 [+ or -] 16.11% vs. 87.60 [+ or -] 8.15%, respectively; (p Protein C and protein S are sensitive markers of hepatocyte synthetic impairment and are valuable markers in monitoring the efficacy of antiviral treatment in chronic hepatitis C patients. Larger studies are needed to confirm our results. KEY WORDS: chronic hepatitis C, liver disease, interferon alpha, anticoagulation proteins, Protein C, Protein S